# Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies

> **NCT00625092** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 17 (actual)

## Conditions studied

- Peritoneal Cavity Cancer

## Interventions

- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin
- **PROCEDURE:** cytoreductive surgery

## Key facts

- **NCT ID:** NCT00625092
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-01
- **Final completion:** 2011-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625092, "Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00625092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*